MOUNTAIN VIEW, Calif., Nov. 17 Based on its recentanalysis of the central stations patient monitoring market, Frost & Sullivanrecognizes OBS Medical with the 2008 North American Frost & SullivanTechnology Innovation Award for its cutting edge Visensia(R) Hospital PatientSafety Suite. Instead of monitoring single parameter deviations as traditionaldevices do, Visensia(R) utilizes revolutionary technology which integrates theclinical values of five vital sign parameters (heart rate, blood pressure,SpO2, skin temperature, and respiratory rate) into a more meaningful andinsightful parameter, expressed as a numerical index (the Visensia(R) Index).This Index represents the patient's wellness in real-time.
Faster emergency response times have improved patient outcomes, as well asreduced operational costs and expensive re-admissions. This has caused thepatient monitoring industry to focus on innovations in connectivity andmonitoring intelligence. While most new solutions are developed on the samebasic and similar platforms, OBS Medical has broken new ground with itsinnovative approach to vital sign interpretation. Its safety suite not onlyhelps detect abnormalities earlier but also nearly eliminates false-positivesproduced by individual vital sign monitoring.
"Unlike the traditional monitoring algorithms, the Visensia(R) is not aone-size-fits-all application; it personalizes patient monitoring byevaluating the 'normal' thresholds for individual patients the and Visensia(R)Index against pre-measured normal thresholds," says Frost & Sullivan ResearchAnalyst Mike Arani. "The addition of this innovative solution to any monitoredunit will greatly boost alarm integrity and timeliness."
Alarming facilitates centralized monitoring by alerting clinicians to thepatients that require immediate care. Low alarm integrity could compromiseclinical workflow and efficiency. Therefore, hospitals seek monitoringsolutions that can enhance alarm accuracy and confidence in critical careapplications.
There has been a growing trend in patient monitoring alerting systems toimplement "secondary" alarm notifications generated at the central stations.These alarms are based on preconfigured algorithms, wherein an alert is sentto the rapid response team (RRT) when the alarm conditions are met.
Clinical trials of the Visensia(R) suite have proven that approximately95 percent of the alerts generated by Visensia(R) were true. Moreover,Visensia(R) VitalAlert(TM) has detected 100 percent of severe clinicaldeterioration (requiring MET/RRT call) with a mean advanced warning of6.3 hours.
"The Visensia(R) Hospital Patient Safety Suite can be integrated with anypatient monitoring solution in the market," notes Arani. "It can collect andanalyze all five vital parameters from conventional bedside or telemetrymonitors, thus enhancing the hospital's existing monitoring system without theneed for costly upgrades."
Each year, Frost & Sullivan presents this award to the company that hasdemonstrated technological innovation within its industry. This Awardrecognizes the ability of the company to successfully develop and introducenew/disruptive technology, formulate a well-designed product family, and makesignificant technology contributions to the industry.
Frost & Sullivan's Best Practices Awards recognize companies in a varietyof regional and global markets for demonstrating outstanding achievement andsuperior performance in areas such as leadership, technological innovation,customer service, and strategic product development. Industry analysts comparemarket participants and measure performance through in-depth interviews,analysis, and extensive secondary research in order to identify best practicesin the industry.
About OBS Medical
OBS Medical delivers life-saving insight through its innovative clinicalsolutions for safer hospitals, safer patients and safer drugs. Based onintelligent algorithms such as neural networks, data fusion and waveformrecognition, these technologies cover a range of medical applicationsincluding automated early crisis warning (Visensia(R)) and efficient cardiacsafety for pharmaceutical research and development (BioQT(TM)). OBS Medicalis in Carmel, Indiana and is a wholly-owned subsidiary of Oxford BioSignalsLtd. based in Oxford, UK, which was originally spun out from OxfordUniversity.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, partners with clients toaccelerate their growth. The company's TEAM Research, Growth Consulting andGrowth Team Membership(TM) empower clients to create a growth-focused culturethat generates, evaluates and implements effective growth strategies. Frost &Sullivan employs over 45 years of experience in partnering with Global 1000companies, emerging businesses and the investment community from more than30 offices on six continents. For more information about Frost & Sullivan'sGrowth Partnership Services, visit http://www.awards.frost.com.Contact: Meredith Formsma 317.819.3950 email@example.com
SOURCE Frost & Sullivan